Drugs / Autologous genetically modified gamma-delta T cells
Autologous genetically modified gamma-delta T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05664243 | Sep 2023 → Dec 2025 overdue | glioblastoma | In8bio Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous genetically modified gamma-delta T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05664243 ↗ |
| Known as | DeltEx | “This is a Phase 1b and 2 open-label cellular therapy trial using genetically modified gamma-delta (γδ) T cells or DeltEx Drug Resistant Immunotherapy (DRI).” NCT05664243 ↗ |
| Known as | DRI | “This is a Phase 1b and 2 open-label cellular therapy trial using genetically modified gamma-delta (γδ) T cells or DeltEx Drug Resistant Immunotherapy (DRI).” NCT05664243 ↗ |
| Route | Other | “are administered through a catheter directly into the brain” NCT05664243 ↗ |